Immatics (NASDAQ:IMTX) Rating Reiterated by Cantor Fitzgerald

Immatics (NASDAQ:IMTX)‘s stock had its “overweight” rating reaffirmed by equities research analysts at Cantor Fitzgerald in a report released on Thursday, Benzinga reports.

Separately, Mizuho increased their price objective on shares of Immatics from $14.00 to $16.00 and gave the stock a “buy” rating in a report on Thursday, May 16th.

Immatics Stock Down 0.5 %

Shares of NASDAQ:IMTX traded down $0.06 on Thursday, reaching $11.18. 94,657 shares of the company’s stock were exchanged, compared to its average volume of 456,919. The firm has a market capitalization of $946.48 million, a price-to-earnings ratio of -10.55 and a beta of 0.75. Immatics has a fifty-two week low of $7.15 and a fifty-two week high of $13.77. The business’s 50-day moving average is $11.77 and its two-hundred day moving average is $11.58.

Immatics (NASDAQ:IMTX) last issued its earnings results on Tuesday, August 13th. The company reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.17. Immatics had a negative net margin of 103.99% and a negative return on equity of 23.34%. The company had revenue of $20.19 million for the quarter, compared to analysts’ expectations of $12.36 million. Analysts predict that Immatics will post -1.03 earnings per share for the current fiscal year.

Institutional Trading of Immatics

A number of large investors have recently modified their holdings of the company. Jump Financial LLC increased its stake in Immatics by 19.8% during the 4th quarter. Jump Financial LLC now owns 48,484 shares of the company’s stock valued at $511,000 after buying an additional 8,014 shares during the period. Trexquant Investment LP increased its stake in Immatics by 4.2% during the 4th quarter. Trexquant Investment LP now owns 44,773 shares of the company’s stock valued at $471,000 after buying an additional 1,801 shares during the period. TD Asset Management Inc increased its stake in Immatics by 14.9% during the 4th quarter. TD Asset Management Inc now owns 227,118 shares of the company’s stock valued at $2,392,000 after buying an additional 29,400 shares during the period. RTW Investments LP increased its stake in Immatics by 75.7% during the 4th quarter. RTW Investments LP now owns 1,484,911 shares of the company’s stock valued at $15,636,000 after buying an additional 639,911 shares during the period. Finally, Vestal Point Capital LP acquired a new position in Immatics during the 4th quarter valued at about $22,113,000. Institutional investors and hedge funds own 64.41% of the company’s stock.

About Immatics

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.